The Efficacy and Safety of Nabilone (A Synthetic Cannabinoid) in the Treatment of Anxiety
Abstract
Abstract: The anxiolytic properties of nabilone, a synthetic cannabinoid resembling the natural cannabinoids, were studied in 25 outpatients suffering from anxiety. The drug was compared with a placebo in a double‐blind manner over a 28‐day treatment period. Patients were seen weekly by the physician and were rated by the Hamilton Rating Scale for Anxiety and the Patient's Global Evaluation as well as by patient‐rated evaluations. The results of the study showed a dramatic improvement in anxiety in the nabilone group when compared with placebo ( P < 0.001). Side effects reported were dry mouth, dry eyes, and drowsiness. Patients did not report any of the subjective “altered state” experience of marihuana.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nabilone is a synthetic cannabinoid CB1-receptor agonist, well-tolerated and with a good safety profile.
“Nabilone is a synthetic cannabinoid CB1-receptor agonist (licensed in Canada since 1981 for chemotherapy-induced vomiting and nausea); it is well-tolerated and has a good safety profile [22, 23].”
From Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial (2012) · cites this paper as [22]
THC administration can reduce anxiety in patients with anxiety disorders.
“studies in controlled clinical settings confirm that administration of synthetic variants of delta-9-tetrahydrocannabinol (THC), the psychoactive constituent of cannabis, can reduce anxiety in patients with anxiety disorders [7,8]”
From Amygdala FAAH and anandamide: mediating protection and recovery from stress (2013) · cites this paper as [7]
Cites
The therapeutic potential of cannabis
Baker, D., Pryce, G., Giovannoni, G., & Thompson, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00381-8 · Cited by 344 · see citing works
Clinical pharmacology of nabilone, a cannabinol derivative
Lemberger, L., & Rowe, H. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1975186720 · Cited by 74 · see citing works
Nakano, S., Gillespie, H. K., & Hollister, L. E. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197823154 · Cited by 59 · see citing works
Single‐Dose Study of Nabilone in Anxious Volunteers
Glass, R. M., UHLENHUTH, E. H., Hartel, F. W., Schuster, C. R., & Fischman, M. W. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02618.x · Cited by 45 · see citing works
Does marijuana enhance experimentally induced anxiety?
Pillard, R. C., McNair, D. M., & Fisher, S. (1974) · Psychopharmacology · doi:10.1007/bf00429414 · Cited by 30 · see citing works
Changes in Anxiety Feelings Following Marihuana Smoking
Abel, E. L. (1971) · British Journal of Addiction to Alcohol & Other Drugs · doi:10.1111/j.1360-0443.1971.tb02384.x · Cited by 25 · see citing works
McLendon, D. M., Harris, R. T., & Maule, W. F. (1976) · Psychopharmacology · doi:10.1007/bf00430486 · Cited by 13 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · see citing works
Interneuron Diversity series: Rhythm and mood in perisomatic inhibition
Freund, T. F. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00227-3 · Cited by 641 · see citing works
Black, N., Stockings, E., Campbell, G., Tran, L. T., Zagic, D., Hall, W. D., Farrell, M., & Degenhardt, L. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30401-8 · Cited by 564 · see citing works
Ligresti, A., PETROCELLIS, L. D., & Marzo, V. D. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 484 · see citing works
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440 · see citing works
Cannabis and anxiety: a critical review of the evidence
Crippa, J. A., Zuardi, A. W., Martín‐Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar‐Poli, P. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1048 · Cited by 509 · see citing works
The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
Haller, J., Bakos, N., Szirmay, M., Ledent, C., & Freund, T. F. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02192.x · Cited by 354 · see citing works
Fraser, G. A. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00071.x · Cited by 283 · see citing works
Therapeutic aspects of cannabis and cannabinoids
Robson, P. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.2.107 · Cited by 265 · see citing works
Hill, M. N., Campolongo, P., Yehuda, R., & Patel, S. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.162 · Cited by 239 · see citing works
Amygdala FAAH and anandamide: mediating protection and recovery from stress
Gunduz-Cinar, O., Hill, M. N., McEwen, B. S., & Holmes, A. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.08.008 · Cited by 229 · see citing works
The endocannabinoid nervous system
Porter, A. C., & Felder, C. C. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00130-9 · Cited by 226 · see citing works
Cannabinoids in health and disease
Kogan, N. M., & Mechoulam, R. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/nkogan · Cited by 227 · see citing works
Adverse effects of cannabis and cannabinoids
Ashton, C. H. (1999) · British Journal of Anaesthesia · doi:10.1093/bja/83.4.637 · Cited by 213 · see citing works
Hill, M. N., & Gorzalka, B. B. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00006 · Cited by 193 · see citing works
Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy
Bar-Lev Schleider, L., Mechoulam, R., Saban, N., Meiri, G., & Novack, V. (2019) · Scientific Reports · doi:10.1038/s41598-018-37570-y · Cited by 186 · see citing works
Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality
Naidu, P. S., Varvel, S. A., Ahn, K., Cravatt, B. F., Martin, B. R., & Lichtman, A. H. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0689-4 · Cited by 184 · see citing works
Adult Neurogenesis and Mental Illness
Schoenfeld, T. J., & Cameron, H. A. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.230 · Cited by 183 · see citing works
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181 · see citing works
Trends in the Development of New Antidepressants. Is there a Light at the End of the Tunnel?
Pacher, P., & Kecskeméti, V. (2004) · Current Medicinal Chemistry · doi:10.2174/0929867043455594 · Cited by 176 · see citing works
Lim, K., See, Y. M., & Lee, J. (2017) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2017.15.4.301 · Cited by 166 · see citing works
Cannabinoid facilitation of fear extinction memory recall in humans
Rabinak, C. A., Angstadt, M., Sripada, C. S., Abelson, J. L., Liberzon, I., Milad, M. R., & Phan, K. L. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.063 · Cited by 163 · see citing works
Different Effects of Nabilone and Cannabidiol on Binocular Depth Inversion in Man
Leweke, F. M., Schneider, U., Radwan, M., Schmidt, E., & Emrich, H. M. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00201-x · Cited by 150 · see citing works
Endocannabinoid system dysfunction in mood and related disorders
Ashton, C. H., & Moore, P. B. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01687.x · Cited by 145 · see citing works
Endocannabinoid System Components as Potential Biomarkers in Psychiatry
Navarrete, F., García‐Gutiérrez, M. S., Barba, R. J., Rubio, G., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00315 · Cited by 134 · see citing works
Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential
Ashton, C. H., Moore, P. B., Gallagher, P., & Young, A. H. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105051541 · Cited by 132 · see citing works
Hill, M. N., & Patel, S. (2013) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-3-19 · Cited by 117 · see citing works
Pini, L. A., Guerzoni, S., Cainazzo, M. M., Ferrari, A., Sarchielli, P., Tiraferri, I., Ciccarese, M., & Zappaterra, M. (2012) · The Journal of Headache and Pain · doi:10.1007/s10194-012-0490-1 · Cited by 107 · see citing works
Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?
Turna, J., Patterson, B. A., & Ameringen, M. V. (2017) · Depression and Anxiety · doi:10.1002/da.22664 · Cited by 101 · see citing works
Experience with the Synthetic Cannabinoid Nabilone in Chronic Noncancer Pain
Berlach, D. M., Shir, Y., & Ware, M. A. (2006) · Pain Medicine · doi:10.1111/j.1526-4637.2006.00085.x · Cited by 96 · see citing works
A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting
Ware, M. A. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1132 · Cited by 89 · see citing works
Tambaro, S., & Bortolato, M. (2011) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488912798842269 · Cited by 89 · see citing works
Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review
Stanciu, C. N., Brunette, M. F., Teja, N., & Budney, A. J. (2021) · Psychiatric Services · doi:10.1176/appi.ps.202000189 · Cited by 86 · see citing works
Endocannabinoids, cannabinoids and the regulation of anxiety
Petrie, G. N., Nastase, A. S., Aukema, R. J., & Hill, M. N. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108626 · Cited by 85 · see citing works
Uso terapêutico dos canabinoides em psiquiatria
Crippa, J. A. S., Zuardi, A. W., & Hallak, J. E. C. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000500009 · Cited by 85 · see citing works
Human Studies of Cannabinoids and Medicinal Cannabis
Robson, P. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_25 · Cited by 76 · see citing works
van Drooge, D. J., Hinrichs, W. L. J., Dickhoff, B. H. J., Elli, M., Visser, M. R., Zijlstra, G. S., & Frijlink, H. W. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.06.007 · Cited by 73 · see citing works
Classical and novel approaches to the preclinical testing of anxiolytics: A critical evaluation
Haller, J., Aliczki, M., & Gyimesi-Pelczer, K. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.09.001 · Cited by 69 · see citing works
Turna, J., Simpson, W. S., Patterson, B. A., Lucas, P., & Ameringen, M. V. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.024 · Cited by 69 · see citing works
Safety Considerations in Cannabinoid-Based Medicine
Gottschling, S., Ayonrinde, O., Bhaskar, A., Blockman, M., D’Agnone, O., Schecter, D., Rodríguez, L. D. S., Yafai, S., & Cyr, C. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s275049 · Cited by 71 · see citing works
Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review
Hasbi, A., Madras, B. K., & George, S. R. (2023) · Brain Sciences · doi:10.3390/brainsci13020325 · Cited by 68 · see citing works
Developmental regulation of fear learning and anxiety behavior by endocannabinoids
Lee, T. T.-Y., Hill, M. N., & Lee, F. S. (2015) · Genes Brain & Behavior · doi:10.1111/gbb.12253 · Cited by 67 · see citing works
The abuse potential of the synthetic cannabinoid nabilone
Ware, M. A., & St Arnaud‐Trempe, E. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02776.x · Cited by 66 · see citing works
Meet Your Stress Management Professionals: The Endocannabinoids
deRoon‐Cassini, T. A., Stollenwerk, T. M., Beatka, M. J., & Hillard, C. J. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.07.002 · Cited by 66 · see citing works
Targeting the endocannabinoid system to treat anxiety-related disorders
Korem, N., Zer‐Aviv, T. M., Ganon-Elazar, E., Abush, H., & Akirav, I. (2015) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2015-0058 · Cited by 64 · see citing works
Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial
Martin, E. L., Strickland, J. C., Schlienz, N. J., Munson, J., Jackson, H., Bonn‐Miller, M. O., & Vandrey, R. G. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.729800 · Cited by 62 · see citing works
Ward, A., & Holmes, B. (1985) · Drugs · doi:10.2165/00003495-198530020-00002 · Cited by 59 · see citing works
Onaivi, E. S., Chakrabarti, A. K., & Chaudhuri, G. (1996) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00044-5 · Cited by 55 · see citing works
The Endocannabinoid System and Anxiety
Lisboa, S. F. D. S., Gomes, F. V., Terzian, A. L. B., de Aguiar, D. C., Moreira, F. A., Resstel, L. B. M., & Guimarães, F. S. (2016) · Vitamins and hormones · doi:10.1016/bs.vh.2016.09.006 · Cited by 56 · see citing works
Kamal, B., Kamal, F., & Lantela, D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00730 · Cited by 57 · see citing works
Cannabis use improves retention and virological outcomes in patients treated for hepatitis C
Sylvestre, D. L., Clements, B. J., & Malibu, Y. (2006) · European Journal of Gastroenterology & Hepatology · doi:10.1097/01.meg.0000216934.22114.51 · Cited by 54 · see citing works
Solid dispersions based on inulin for the stabilisation and formulation of Δ9-tetrahydrocannabinol
van Drooge, D. J., Hinrichs, W. L. J., Wegman, K. A. M., Visser, M. R., Eissens, A. C., & Frijlink, H. W. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2003.11.014 · Cited by 49 · see citing works
Rabinak, C. A., & Phan, K. L. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990437 · Cited by 46 · see citing works
McKee, K. A., Hmidan, A., Crocker, C. E., Lam, R. W. M., Meyer, J. H., Crockford, D. N., Trépanier, A., Aitchison, K. J., & Tibbo, P. G. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.044 · Cited by 44 · see citing works
The role of cannabis in treating anxiety
Ameringen, M. V., Zhang, J., Patterson, B. A., & Turna, J. (2019) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000566 · Cited by 43 · see citing works
Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence
Célèrier, E., Ahdepil, T., Wikander, H., Berrendero, F., Nyberg, F., & Maldonado, R. J. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.11.017 · Cited by 43 · see citing works
Cannabinoids as therapeutic for PTSD
Loflin, M., Babson, K. A., & Bonn‐Miller, M. O. (2016) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2016.12.001 · Cited by 42 · see citing works
Effects of ∆9-tetrahydrocannabinol on aversive memories and anxiety: a review from human studies
Raymundi, A. M., da Silva, T. R., Sohn, J. M. B., Bertoglio, L. J., & Stern, C. A. J. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02813-8 · Cited by 40 · see citing works
Batista, L. A., Gobira, P. H., Viana, T. G., de Aguiar, D. C., & Moreira, F. A. (2014) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000073 · Cited by 38 · see citing works
Ergisi, M., Erridge, S., Harris, M., Kawka, M., Nimalan, D., Salazar, O., Loupasaki, K., Ali, R., Holvey, C., Coomber, R., et al. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2020640 · Cited by 39 · see citing works
Bahji, A., Meyyappan, A. C., & Hawken, E. R. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.07.030 · Cited by 36 · see citing works
Cannabis, Cannabinoids, and Brain Morphology: A Review of the Evidence
Chye, Y., Kirkham, R., Lorenzetti, V., McTavish, E., Solowij, N., & Yücel, M. (2020) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2020.07.009 · Cited by 34 · see citing works
Thumma, S., ElSohly, M. A., Zhang, S., Gul, W., & Repka, M. A. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.06.009 · Cited by 34 · see citing works
Cannabis and anticancer drugs: societal usage and expected pharmacological interactions – a review
Bouquié, R., Deslandes, G., Mazaré, H., Cogné, M., Mahé, J., Grégoire, M., & Jolliet, P. (2018) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12373 · Cited by 34 · see citing works
Drugs related to tetrahydrocannabinol
Razdan, R. K., & Howes, J. F. (1983) · Medicinal Research Reviews · doi:10.1002/med.2610030203 · Cited by 32 · see citing works
Cannabis as medicine: time for the phoenix to rise?
Robson, P. (1998) · BMJ · doi:10.1136/bmj.316.7137.1034 · Cited by 32 · see citing works
Costiniuk, C. T., Mills, E. J., & Cooper, C. (2008) · Canadian Journal of Gastroenterology · doi:10.1155/2008/725702 · Cited by 30 · see citing works
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C. R., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19203 · Cited by 27 · see citing works
Biomedical benefits of cannabinoids?
Ashton, C. H. (1999) · Addiction Biology · doi:10.1080/13556219971623 · Cited by 22 · see citing works
Meffert, B. N., Morabito, D. M., Mosich, M. K., Loflin, M., Sottile, J. E., & Heinz, A. J. (2018) · Current Drug Research Reviews · doi:10.2174/2589977511666181109153958 · Cited by 20 · see citing works
Cannabinoids in anaesthesia and pain therapy
Azad, S. C., & Rammes, G. (2005) · Current Opinion in Anaesthesiology · doi:10.1097/01.aco.0000174959.05383.9c · Cited by 19 · see citing works
Kibret, B. G. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.09.019 · Cited by 17 · see citing works
(1998) · CRC Press eBooks · doi:10.1201/9780203304228 · Cited by 16 · see citing works
Belgers, V., Röttgering, J. G., Douw, L., Klein, M., Ket, J. C. F., van de Ven, P. M., Wurdinger, T. D., Linde, M. E. V., Niers, J. M., Weber, M., et al. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0187 · Cited by 19 · see citing works
Vulnerability Factors for the Psychiatric and Behavioral Effects of Cannabis
Bortolato, M., Bini, V., & Tambaro, S. (2010) · Pharmaceuticals · doi:10.3390/ph3092799 · Cited by 14 · see citing works
The differential effects of medicinal cannabis on mental health: A systematic review
de Bode, N., Kroon, E., Sznitman, S. R., & Cousijn, J. (2025) · Clinical Psychology Review · doi:10.1016/j.cpr.2025.102581 · Cited by 13 · see citing works
Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?
Tibbo, P. G., McKee, K. A., Meyer, J. H., Crocker, C. E., Aitchison, K. J., Lam, R. W. M., & Crockford, D. N. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720945525 · Cited by 13 · see citing works
Uso terapéutico de los cannabinoides
Durán, M., & Capellà, D. (2004) · Adicciones · doi:10.20882/adicciones.412 · Cited by 13 · see citing works
Tavhare, S. D., Acharya, R., Reddy, R. G., & Dhiman, K. S. (2019) · AYU (An International Quarterly Journal of Research in Ayurveda) · doi:10.4103/ayu.ayu_43_19 · Cited by 12 · see citing works
Tetrahydrocannabinols: potential cannabimimetic agents for cancer therapy
Prateeksha, P., Sharma, V. K., Singh, S. M., Sharma, M., Diwan, D., Hesham, A. E., Guleria, S., Nguyen, Q. D., Gupta, V. K., & Singh, B. N. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10078-2 · Cited by 11 · see citing works
Comparison of Bronchial Effects of Nabilone and Terbutaline in Healthy and Asthmatic Subjects
Gong, H., Tashkin, D. P., & Calvarese, B. M. (1983) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1983.tb02715.x · Cited by 11 · see citing works
Bondok, M., Nguyen, A. X.-L., Landó, L., & Wu, A. Y. (2024) · Clinical ophthalmology · doi:10.2147/opth.s501494 · Cited by 11 · see citing works
Adejumo, A., Ajayi, T. O., Adegbala, O. M., & Bukong, T. N. (2019) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001382 · Cited by 10 · see citing works
Balter, R. E., & Haney, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00099-5 · Cited by 9 · see citing works
Medicinal cannabis in the management of anxiety disorders: A systematic review
Roberts, L., Sorial, E., Budgeon, C. A., Lee, K., Preen, D. B., & Cumming, C. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116552 · Cited by 11 · see citing works
(2014) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63430-6.00009-6 · Cited by 8 · see citing works
Delatte, M. S., & Paronis, C. A. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0918-5 · Cited by 8 · see citing works
Chapter 4.5 The endocannabinoid system and anxiety responses
Bortolato, M., & Piomelli, D. (2008) · Handbook of Behavioral Neuroscience · doi:10.1016/s1569-7339(07)00014-8 · Cited by 7 · see citing works
Utilidad terapéutica del Cannabis y derivados
Lorenzo, P., & Leza, J. C. (2000) · Adicciones · doi:10.20882/adicciones.678 · Cited by 7 · see citing works
Cannabinoid-Based Drugs: Potential Applications in Addiction and Other Mental Disorders
Don, W., & Piomelli, D. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20150009 · Cited by 7 · see citing works
Robson, P. (1997) · Archives of Disease in Childhood · doi:10.1136/adc.77.2.164 · Cited by 6 · see citing works
Cannabis Science and Therapeutics: An Overview for Clinicians
Sera, L., & Hempel-Sanderoff, C. (2023) · Journal of clinical pharmacology · doi:10.1002/jcph.2400 · Cited by 2 · see citing works
Minhas, M., & Lunn, S. E. (2023) · Journal of Cannabis Research · doi:10.1186/s42238-023-00192-x · Cited by 4 · see citing works
An EEG investigation on nabilone, a synthetic cannabinoid, in rabbits
Sagratella, S., Pèzzola, A., & de Carolis, A. S. (1986) · Pharmacological Research Communications · doi:10.1016/0031-6989(86)90107-4 · Cited by 4 · see citing works
Yang, T.-K. (2005) · Texas ScholarWorks (Texas Digital Library) · Cited by 4 · see citing works
Unseen dualities: underdiagnosis of substance use disorders in borderline personality disorder
Nabel, J., Bertele, S., Stapel, B., Scharn, N., & Kahl, K. G. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1539611 · Cited by 3 · see citing works
Cannabinoid Drugs in Mental Health Disorders
Kloiber, S. M., Matheson, J., Kim, H. K., & Foll, B. L. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_465-1 · Cited by 3 · see citing works
Schecter, D., & Cyr, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-89918-9_7 · Cited by 3 · see citing works
Use of cannabis in medicine and pharmacy
Goločorbin-Kon, S., Pavlović, N., Rašković, A., Lalic-Popovic, M. N., Milić, N., Milosevic, N. P., & Mikov, M. (2015) · Medicinski casopis · doi:10.5937/mckg49-9796 · Cited by 3 · see citing works
Komaki, A., Haghgooyan, A., Shahidi, ., Sarihi, A., & Salehi, I. (2014) · Avicenna Journal of Neuro Psych Physiology · doi:10.17795/ajnpp-24450 · Cited by 2 · see citing works
- Authors
- FABRE, L. F., & McLENDON, D.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1981-08-09
- Volume
- 21
- Issue
- S1
- Pages
- 377S-382S
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2140255682
- Cited by
- 138
- References
- 7
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 13 · 2022: 11 · 2021: 9 · 2020: 10 · 2019: 7 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 6 · 2014: 5 · 2013: 3 · 2012: 4
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- nabilone, synthetic cannabinoids, anxiety, anxiolytic efficacy, drug safety, placebo comparison, adverse effects, xerostomia, sleepiness, cannabis
- MeSH terms
- Adolescent, Adult, Anxiety Disorders, Clinical Trials as Topic, Double-Blind Method, Female, Humans, Male, Middle Aged, Placebos, Psychiatric Status Rating Scales, Dronabinol, Time Factors, Anti-Anxiety Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
